MG53：一种潜在的肾脏疾病治疗靶点。

MG53: A potential therapeutic target for kidney disease.

机构信息

Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.

Department of Cardiovascular Medicine, The Second Affiliated Hospital to Nanchang University, Nanchang, China.

出版信息

Pharmacol Res Perspect. 2023 Feb;11(1):e01049. doi: 10.1002/prp2.1049.

DOI:10.1002/prp2.1049

PMID:36583464

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9801490/

Abstract

Ensuring cell survival and tissue regeneration by maintaining cellular integrity is important to the pathophysiology of many human diseases, including kidney disease. Mitsugumin 53 (MG53) is a member of the tripartite motif-containing (TRIM) protein family that plays an essential role in repairing cell membrane injury and improving tissue regeneration. In recent years, an increasing number of studies have demonstrated that MG53 plays a renoprotective role in kidney diseases. Moreover, with the beneficial effects of the recombinant human MG53 (rhMG53) protein in the treatment of kidney diseases in different animal models, rhMG53 shows significant therapeutic potential in kidney disease. In this review, we elucidate the role of MG53 and its molecular mechanism in kidney disease to provide new approaches to the treatment of kidney disease.

摘要

维持细胞完整性以确保细胞存活和组织再生对于许多人类疾病的病理生理学都很重要，包括肾脏疾病。Mitsugumin 53（MG53）是三部分基序（TRIM）蛋白家族的成员，在修复细胞膜损伤和改善组织再生方面发挥着重要作用。近年来，越来越多的研究表明，MG53 在肾脏疾病中具有肾保护作用。此外，由于重组人 MG53（rhMG53）蛋白在不同动物模型中的肾脏疾病治疗中具有有益效果，rhMG53 在肾脏疾病中具有显著的治疗潜力。在这篇综述中，我们阐明了 MG53 的作用及其在肾脏疾病中的分子机制，为肾脏疾病的治疗提供了新的途径。